Promega to provide FuGENE HD Transfection Reagent throughout life science market

Promega Corporation announces it will provide FuGENE® HD Transfection Reagent throughout the life science market. The comprehensive, direct use offering from Promega means any life scientist can utilize FuGENE technology with no licensing requirements. FuGENE HD enables the transfection of DNA into many cell types with high efficiency and little-to-no toxicity.

“FuGENE HD means robust performance and ease in handling. Pairing this industry standard gene delivery technology with luciferase reporter assays and other relevant Promega detection technologies will enable manipulation of biological models that better represent native biological systems of interest”

FuGENE HD easily integrates with the sensitive luciferase reporter assays and other cell-based reporter systems offered by Promega including HaloTag® technology for protein manipulation and the GloSensor™ live-cell sensor technology. "FuGENE HD means robust performance and ease in handling. Pairing this industry standard gene delivery technology with luciferase reporter assays and other relevant Promega detection technologies will enable manipulation of biological models that better represent native biological systems of interest," said Kevin Kopish, Strategic Marketing Manager at Promega.

FuGENE HD also has benefits that render it ideal for use in biopharmaceutical drug discovery. With excellent performance in chemically defined media and being free of animal-derived components, this transfection reagent can be used for protein or virus manufacturing at bench-level research to full-scale biologics production.

Source:

Promega Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Possible impact of spike protein mutations on SARS-CoV-2 Omicron variant